 |
28. Effectiveness of postprandial Humalog in toddlers with diabetes/K.S. Rutledge [et al.]//Pediatrics. - 1997. - Vol. 100. - N 6. - P. 968 - 972.
|
|
|
|
18. ISPAD Clinical Practice Consensus Guidelines 2018: Glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes/L. A. DiMeglio [et al. ]//Pediatric Diabetes. - 2018. - Vol. 19. - P. 105 - 114.
19. Avoidance of hypoglycemia restores hypoglycemia awareness by increasing beta-adrenergic sensitivity in type 1 diabetes/A. Fritsche [et al. ]//Annals of Internal Medicine. - 2001. - Vol. 134. - N 9 Pt 1. - P. 729 - 736.
20. Both the frequency of HbA1c testing and the frequency of self-monitoring of blood glucose predict metabolic control: A multicentre analysis of 15 199 adult type 1 diabetes patients from Germany and Austria/A. Schwandt [et al. ]//Diabetes/Metabolism Research and Reviews. - 2017. - Vol. 33. - N 7.
21. Reduced testing frequency for glycated hemoglobin, HbA1c, is associated with deteriorating diabetes control/O. J. Driskell [et al. ]//Diabetes Care. - 2014. - Vol. 37. - N 10. - P. 2731 - 2737.
22. A randomised, open-labelstudy of insulin glargine or neutral protamine Hagedorn insulin in Chinese paediatric patients with type 1 diabetes mellitus/M. Liu [et al. ]//BMC endocrine disorders. - 2016. - Vol. 16. - N 1. - P. 67.
23. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus/E. Schober [et al. ]//Journal of pediatric endocrinology & metabolism: JPEM. - 2002. - Vol. 15. - N 4. - P. 369 - 376.
24. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes/T. Danne [et al. ]//Diabetes Care. - 2005. - Vol. 28. - N 9. - P. 2100 - 2105.
25. Comparable Efficacy and Safety of Insulin Glulisine and Insulin Lispro When Given as Part of a Basal-Bolus Insulin Regimen in a 26-Week Trial in Pediatric Patients with Type 1 Diabetes/A. Philotheou [et al. ]//Diabetes Technology & Therapeutics. - 2011. - Vol. 13. - N 3. - P. 327 - 334.
26. Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents/J. H. Holcombe [et al. ]//Clinical Therapeutics. - 2002. - Vol. 24. - N 4. - P. 629 - 638.
27. Post-prandial insulin lispro vs. human regular insulin in prepubertal children with Type 1 diabetes mellitus/S. Tupola [et al. ]//Diabetic Medicine: A Journal of the British Diabetic Association. - 2001. - Vol. 18. - N 8. - P. 654 - 658.
28. Effectiveness of postprandial Humalog in toddlers with diabetes/K. S. Rutledge [et al. ]//Pediatrics. - 1997. - Vol. 100. - N 6. - P. 968 - 972.
29. Insulin Lispro Lowers Postprandial Glucose in Prepubertal Children With Diabetes/L. C. Deeb [et al. ]//PEDIATRICS. - 2001. - Vol. 108. - N 5. - P. 1175 - 1179.
30. Efficacy and safety of a fixed combination of insulin degludec/insulin aspart in children and adolescents with type 1 diabetes: A randomized trial/T. Battelino [et al. ]//Pediatric Diabetes. - 2018. - Vol. 19. - N 7. - P. 1263 - 1270.
|
|
|
31. Switching From Glargine to Degludec: The Effect on Metabolic Control and Safety During 1-Year of Real Clinical Practice in Children and Adolescents With Type 1 Diabetes/B. Predieri [и др. ]//Frontiers in Endocrinology. - 2018. - T. 9. - C. 462.
32. The rate of hyperglycemia and ketosis with insulin degludec-based treatment compared with insulin detemir in pediatric patients with type 1 diabetes: An analysis of data from two randomized trials/N. Thalange [et al. ]//Pediatric Diabetes. - 2019. - Vol. 20. - N 3. - P. 314 - 320.
33. Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes: IDeg effective and safe in pediatric T1D/N. Thalange [et al. ]//Pediatric Diabetes. - 2015. - Vol. 16. - N 3. - P. 164 - 176.
34. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes/T. Danne [et al. ]//Diabetes Care. - 2003. - Vol. 26. - N 11. - P. 3087 - 3092.
35. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes/K. J. Robertson [et al. ]//Diabetic Medicine: A Journal of the British Diabetic Association. - 2007. - Vol. 24. - N 1. - P. 27 - 34.
36. ISPAD Clinical Practice Consensus Guidelines 2018: Insulin treatment in children and adolescents with diabetes/T. Danne [et al. ]//Pediatric Diabetes. - 2018. - Vol. 19. - P. 115 - 135.
37. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group//The Journal of Pediatrics. - 1994. - Vol. 125. - N 2. - P. 177 - 188.
38. Impact of diabetes and its treatment on cognitive function among adolescents who participated in the Diabetes Control and Complications Trial/G. Musen [et al. ]//Diabetes Care. - 2008. - Vol. 31. - N 10. - P. 1933 - 1938.
39. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT)/N. H. White [et al. ]//The Journal of Pediatrics. - 2001. - Vol. 139. - N 6. - P. 804 - 812.
40. Effects of Prior Intensive Insulin Therapy on Cardiac Autonomic Nervous System Function in Type 1 Diabetes Mellitus: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC)/R. Pop-Busui [et al. ]//Circulation. - 2009. - Vol. 119. - N 22. - P. 2886 - 2893.
41. Efficacy and Safety of Rapid-Acting Insulin Analogs in Special Populations with Type 1 Diabetes or Gestational Diabetes: Systematic Review and Meta-Analysis/K. [et al. ]//Diabetes Therapy. - 2018. - Vol. 9. - N 3. - P. 891 - 917.
42. Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamine Hagedorn insulin/H. P. Chase [et al. ]//The Journal of Pediatrics. - 2003. - Vol. 143. - N 6. - P. 737 - 740.
|
|
|
